RPC advises Cardiogeni PLC on its listing on the Aquis Growth Market
International law firm RPC has advised Cardiogeni PLC (Cardiogeni), a UK-based clinical-stage biotechnology company, on its admission to trading on the Access segment of the Aquis Stock Exchange (AQSE).
Trading of Cardiogeni's ordinary shares commenced at 8am today, marking an important milestone. Cardiogeni continues to develop pioneering heart failure treatments.
On admission, Cardiogeni had a market capitalisation of approximately £125.5 million and has secured an equity financing line of up to £100 million share subscription facility from GEM Global Yield LLC SCS.
The RPC corporate team was led by Partner James Channo supported by Rachel Stanley and Hadrian Leung. The team advised Cardiogeni on all legal aspects of its restructuring, and listing process, including transactional documentation. The team’s expertise in capital markets and life sciences ensured a smooth admission process for Cardiogeni.
James Channo remarked: “We are delighted to have supported Cardiogeni on this milestone admission to AQSE. Its cutting-edge approach to regenerative medicine has the potential to transform the treatment of heart failure and this listing will provide our client with the platform to accelerate its clinical research and bring innovative therapies to patients worldwide.”
Darrin Disley, Executive Chairman at Cardiogeni, added: “Today’s admission to AQSE marks the beginning of the next phase of our mission to develop best-in-class allogeneic cell therapy products for heart failure patients. RPC’s guidance has been invaluable throughout the process, and we look forward to continuing our journey with their support.”
Client release: Cardiogeni PLC Admission on AQSE and First Day of Dealings
Stay connected and subscribe to our latest insights and views
Subscribe Here